Cannabis Consumption Trends: Usage Patterns, Demographics & Market Shifts

Executive Summary

Cannabis consumption in the United States reached historic highs in 2026, with daily or near-daily use surpassing alcohol for the first time in recorded survey history. According to data from the National Survey on Drug Use and Health (NSDUH) analyzed by researchers at Carnegie Mellon University and published in May 2026, approximately 17.9 million Americans now use cannabis daily or nearly daily, compared to 14.7 million who drink alcohol at that frequency. This milestone represents a fundamental shift in American substance use patterns, driven by expanding state-level legalization, changing social attitudes, evolving product formats, and generational replacement. The trend carries profound implications for public health policy, the $33.6 billion legal cannabis market, alcohol and pharmaceutical industries, workplace safety protocols, and federal regulatory frameworks that remain misaligned with consumption realities on the ground.

The data reveals that cannabis use has increased approximately 240% since 2002, while daily alcohol consumption has remained relatively flat over the same period. Among adults aged 18-25, cannabis use rates now exceed 30% in states with adult-use legalization, compared to roughly 15% in prohibition states. Product innovation—particularly in vaporizers, edibles, and beverages—has accelerated adoption among demographics historically resistant to smoking, including women over 40 and professionals in white-collar industries. This consumption surge occurs against a backdrop of continued federal prohibition under the Controlled Substances Act (21 U.S.C. § 812), creating a regulatory paradox where the majority of Americans live in states with legal access to a federally illegal substance.

Why This Matters

The normalization of cannabis consumption affects 140 million Americans living in adult-use states, a $100+ billion combined legal and illicit market, and federal policy frameworks built on assumptions no longer supported by population behavior.

For patients, the shift reflects growing acceptance of cannabis as a therapeutic tool for chronic pain, anxiety, insomnia, and other conditions—particularly as opioid prescribing has declined. The CDC reported that opioid prescriptions fell 44% between 2012 and 2025, a period coinciding with medical cannabis expansion in 38 states. Surveys indicate that 60-80% of medical cannabis patients report substituting cannabis for prescription medications, with the highest substitution rates for opioids, benzodiazepines, and sleep aids.

For operators and investors, consumption trends drive market structure. The rise of daily users—who account for an estimated 75-80% of total cannabis purchases—has shifted business models toward loyalty programs, subscription services, and higher-potency products. Multi-state operators including Curaleaf, Green Thumb Industries, Trulieve, and Verano have invested heavily in data analytics to track consumption patterns, with average basket sizes for daily users reaching $85-120 compared to $45-60 for occasional consumers.

For employers, the consumption surge complicates workplace drug policies. Approximately 15-20% of U.S. workers now use cannabis at least monthly, according to Quest Diagnostics workplace testing data, yet most employers maintain zero-tolerance policies inherited from the Drug-Free Workplace Act of 1988. States including New York, New Jersey, Connecticut, Montana, and Nevada have enacted employment protections prohibiting discrimination based on off-duty cannabis use, forcing employers to distinguish between impairment and mere presence of metabolites that can persist for weeks.

For policymakers, the data undermines the foundation of Schedule I classification, which requires a substance to have "no currently accepted medical use" and "high potential for abuse." With daily cannabis use now exceeding daily alcohol use—and alcohol remaining unscheduled—the regulatory asymmetry has become untenable. The Department of Justice's August 2023 recommendation to reschedule cannabis to Schedule III under 21 U.S.C. § 811(a) remains pending before the Drug Enforcement Administration as of May 2026, with a final rule expected in late 2026 or early 2027.

Background and History: From Prohibition to Prevalence

Cannabis consumption patterns have undergone four distinct phases since federal prohibition began in 1937, with the current surge representing the culmination of a 28-year state-level legalization experiment.

The Prohibition Era (1937-1996)

The Marihuana Tax Act of 1937 effectively criminalized cannabis nationwide, followed by formal Schedule I placement under the Controlled Substances Act of 1970. During this period, cannabis use remained largely underground, with prevalence estimates ranging from 5-15% of adults reporting lifetime use in surveys conducted between 1970 and 1990. The "Just Say No" campaign launched by the Reagan administration in 1982 and the Anti-Drug Abuse Act of 1986—which established mandatory minimum sentences for cannabis offenses—reinforced prohibition messaging. Survey data from this era shows past-month cannabis use among adults hovering between 4-6%, with use concentrated among younger demographics and counterculture communities.

Medical Cannabis Emergence (1996-2012)

California's Proposition 215, approved by voters in November 1996, created the first state-legal medical cannabis program, establishing a framework under the Compassionate Use Act. Alaska, Oregon, and Washington followed in 1998, with Maine joining in 1999. By 2012, 18 states and the District of Columbia had enacted medical cannabis laws, creating a patchwork of state-legal access within a federally prohibited framework.

Consumption patterns during this period showed modest increases, with NSDUH data indicating past-month use rising from 6.2% of adults in 1996 to 9.1% in 2012. Medical programs served relatively small patient populations—typically 1-3% of state residents—due to restrictive qualifying conditions, physician reluctance, and stigma. However, these programs established supply chains, normalized cannabis commerce, and created political constituencies that would later support adult-use legalization.

Adult-Use Legalization Wave (2012-2020)

The modern adult-use era began on November 6, 2012, when Colorado and Washington became the first states to legalize cannabis for non-medical use by adults 21 and older. Colorado's Amendment 64 and Washington's Initiative 502 passed with 55% and 56% support, respectively. Retail sales commenced in Colorado on January 1, 2014, and in Washington in July 2014.

Alaska and Oregon legalized in 2014, with sales beginning in 2015-2016. The District of Columbia legalized possession and cultivation in 2015 but prohibited commercial sales due to congressional budget riders. California, Massachusetts, Maine, and Nevada legalized in 2016, with California's Proposition 64 creating the largest legal market in the world when sales began on January 1, 2018. Vermont became the first state to legalize through legislative action in 2018, followed by Michigan through ballot measure the same year.

By the end of 2020, 15 states plus DC had legalized adult use. Consumption data showed accelerating growth, with past-month use reaching 14.2% of adults nationally in 2020, and exceeding 20% in states with mature legal markets. The COVID-19 pandemic appeared to accelerate adoption, with cannabis retailers designated as essential businesses in most legal states and sales increasing 40-50% year-over-year in 2020.

Normalization and Market Maturity (2021-Present)

The period from 2021 to present has seen adult-use legalization reach critical mass. New York legalized in March 2021 through the Marihuana Regulation and Taxation Act, with retail sales beginning in December 2022. New Jersey, Virginia, Connecticut, New Mexico, Rhode Island, Maryland, Missouri, and Delaware legalized between 2021 and 2023. As of May 2026, 24 states plus DC and two territories have legalized adult use, representing 54% of the U.S. population.

Ohio legalized through Issue 2 in November 2023, with sales beginning in August 2024. Florida's Amendment 3 appeared on the November 2024 ballot but failed to reach the required 60% threshold, receiving 57% support. Pennsylvania, Minnesota, and Kentucky have active legalization efforts in their legislatures as of mid-2026.

Consumption during this phase has normalized across demographic groups. NSDUH data shows past-month use reaching 18.1% of adults in 2025, with daily or near-daily use at 8.9%—the metric that surpassed daily alcohol use in 2026. Among adults in legal states, past-month use averages 22-25%, compared to 12-14% in prohibition states, suggesting that legal access increases consumption by approximately 60-80% over prohibition baselines.

Key Players Driving Consumption Trends

Federal Agencies: DEA, FDA, SAMHSA

The Drug Enforcement Administration maintains cannabis as a Schedule I controlled substance under 21 U.S.C. § 812, despite the Department of Justice's August 2023 recommendation to reschedule to Schedule III. The DEA's administrative law judge hearings on rescheduling began in March 2026, with a final rule expected in Q4 2026. The agency's enforcement posture has shifted toward non-interference with state-legal programs, following the Cole Memorandum (2013) and subsequent guidance, though the memo was formally rescinded in 2018.

The Food and Drug Administration regulates cannabis-derived pharmaceuticals including Epidiolex (approved 2018 for epilepsy), Marinol, and Syndros, but lacks authority over state-legal cannabis products due to Schedule I status. The FDA has issued warning letters to companies making unsubstantiated health claims about CBD products and has called for congressional action to establish a regulatory framework for hemp-derived cannabinoids.

The Substance Abuse and Mental Health Services Administration conducts the National Survey on Drug Use and Health, the primary data source for consumption trends. SAMHSA's 2025 survey showed 61.9 million Americans used cannabis in the past year, with 17.9 million using daily or nearly daily.

Multi-State Operators: Curaleaf, Green Thumb, Trulieve, Verano

Curaleaf operates 151 dispensaries across 18 states and reported $1.38 billion in revenue for 2025, making it the largest U.S. cannabis company by sales. The company's consumer data shows that daily users account for 78% of revenue despite representing only 35% of customers, with average annual spending of $3,200 per daily user compared to $580 for occasional consumers.

Green Thumb Industries operates 94 stores across 15 states under the RISE and Cookies brands. The company reported that repeat customers account for 82% of sales, with loyalty program members visiting an average of 2.3 times per month. Green Thumb's 2025 revenue reached $1.12 billion.

Trulieve dominates the Florida medical market with 186 dispensaries and reported $1.31 billion in 2025 revenue. The company's patient data shows 68% of active patients purchase at least twice monthly, with flower products accounting for 54% of sales, pre-rolls 18%, vaporizers 14%, and edibles 9%.

Verano operates 137 dispensaries across 13 states and reported $891 million in 2025 revenue. The company has invested heavily in brand development, with proprietary brands including Avexia, Encore, and MÜV accounting for 71% of sales.

Data and Research Organizations

The Carnegie Mellon University team led by Dr. Jonathan Caulkins published the May 2026 analysis showing daily cannabis use surpassing daily alcohol use, based on NSDUH data from 1992-2025. The research, published in the journal Addiction, noted that cannabis use has increased 240% since 2002 while alcohol use remained flat.

BDSA, a cannabis market research firm, tracks consumption patterns through point-of-sale data from approximately 2,800 dispensaries. The company's 2026 Cannabis Consumer Insights report found that 42% of consumers use cannabis daily, 28% weekly, 18% monthly, and 12% less than monthly. Daily users skew male (58%), aged 35-54 (44%), and prefer flower (62%) over other formats.

Headset, another analytics firm, reported that average transaction sizes increased from $52 in 2020 to $73 in 2025, driven by bulk purchasing by daily users and premiumization. The company's data shows pre-roll sales growing 180% between 2021 and 2025, making them the fastest-growing category.

Advocacy Organizations

The National Organization for the Reform of Marijuana Laws (NORML) has advocated for legalization since 1970. The organization's 2026 survey found that 68% of Americans support legalizing cannabis for adult use, up from 12% in 1970 and 50% in 2012. NORML attributes consumption increases to reduced stigma, improved product quality, and greater accessibility in legal markets.

The Marijuana Policy Project has supported legalization ballot measures in 15 states since 2000. Executive Director Steve Hawkins said in April 2026 that consumption trends validate the organization's position that "cannabis is safer than alcohol and should be regulated similarly."

Legal and Regulatory Framework

Cannabis consumption exists in a legal paradox where state law authorizes activity that remains a federal felony under 21 U.S.C. § 844, creating compliance challenges for consumers, employers, and regulators.

Federal Law: The Controlled Substances Act

The Controlled Substances Act of 1970 (21 U.S.C. § 801 et seq.) places cannabis in Schedule I, defined as substances with "high potential for abuse," "no currently accepted medical use in treatment," and "lack of accepted safety for use under medical supervision." Possession of any amount is a federal misdemeanor under 21 U.S.C. § 844, punishable by up to one year imprisonment and a minimum $1,000 fine for first offense.

The CSA provides no exception for state-legal activity. However, the Rohrabacher-Farr Amendment (now Rohrabacher-Blumenauer), first enacted in 2014 and renewed annually through appropriations bills, prohibits the Department of Justice from using funds to prevent states from "implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana." This protection does not extend to adult-use programs.

The pending rescheduling to Schedule III would not legalize cannabis but would remove criminal penalties for simple possession under federal law, allow businesses to deduct ordinary business expenses under 26 U.S.C. § 280E, and permit medical research under less restrictive protocols. Schedule III substances include ketamine, anabolic steroids, and testosterone.

State Legal Frameworks

State adult-use laws generally authorize possession of 1-2 ounces of flower and cultivation of 3-12 plants for personal use by adults 21 and older. Public consumption remains prohibited in most states, with exceptions for licensed consumption lounges in Alaska, California, Colorado, Nevada, and New Jersey. Driving under the influence is prohibited in all states, though per se THC limits vary from 1 ng/mL (Montana) to 5 ng/mL (Colorado, Washington) to no numeric threshold (California, Oregon).

Medical cannabis laws in 38 states authorize possession of larger quantities—typically 2-10 ounces—for registered patients with qualifying conditions. Conditions vary by state but commonly include cancer, HIV/AIDS, epilepsy, PTSD, chronic pain, and nausea. Seventeen states allow medical cannabis for any condition with physician recommendation.

Employment Law

The Drug-Free Workplace Act of 1988 (41 U.S.C. § 8101 et seq.) requires federal contractors to maintain drug-free workplaces but does not mandate drug testing. Most private employers may terminate employees for cannabis use under at-will employment doctrines, even in legal states, based on the principle that employers need not accommodate illegal activity under federal law.

However, 12 states have enacted employment protections prohibiting discrimination based on off-duty cannabis use. New York's Marihuana Regulation and Taxation Act prohibits employment discrimination based on cannabis use outside work hours, with exceptions for safety-sensitive positions and federal contractors. New Jersey's Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act contains similar protections. Montana, Nevada, Connecticut, Rhode Island, and California have enacted varying levels of protection.

The emerging legal standard distinguishes between impairment—which employers may prohibit—and the presence of non-psychoactive metabolites detected by standard urine tests. Several states require employers to demonstrate actual impairment rather than relying on positive drug tests alone.

State-by-State Consumption Patterns

Consumption rates vary dramatically by state legal status, with adult-use states showing 60-80% higher past-month use than prohibition states, and daily use rates 90-120% higher.

California

California legalized adult use through Proposition 64 in November 2016, with sales beginning January 1, 2018. The state's 39 million residents represent the largest legal cannabis market globally. NSDUH data shows past-month use at 24.1% of adults in 2025, compared to 13.8% in 2016. Daily or near-daily use reached 11.2% in 2025. The California Department of Cannabis Control reported $5.3 billion in legal sales in 2025, though the illicit market remains larger at an estimated $8-10 billion. Possession limit: 1 ounce flower, 8 grams concentrate. Home cultivation: 6 plants per residence.

Colorado

Colorado legalized through Amendment 64 in November 2012, with retail sales beginning January 1, 2014. As the first adult-use state, Colorado provides the longest data series on consumption trends. Past-month use increased from 12.9% in 2012 to 23.8% in 2025. Daily use rose from 5.1% to 10.9% over the same period. The Colorado Department of Revenue reported $1.56 billion in sales in 2025. Youth use rates (ages 12-17) have remained stable at 8-9% since legalization, contrary to predictions of increased adolescent consumption. Possession limit: 1 ounce flower, 8 grams concentrate. Home cultivation: 6 plants per person, 12 per residence.

Florida

Florida operates a medical-only program serving 890,000 registered patients as of May 2026, representing 4.1% of the state's population—the highest medical patient rate nationally. Past-month use reached 15.2% in 2025, up from 8.1% in 2016 when the medical program launched. The November 2024 adult-use ballot measure (Amendment 3) received 57% support but failed to reach the required 60% threshold. Trulieve, the state's dominant operator, reported that 68% of patients purchase at least twice monthly. Medical possession limit: 2.5 ounces flower per 35 days, no concentrate limit. No home cultivation.

Illinois

Illinois legalized adult use through the Cannabis Regulation and Tax Act, effective January 1, 2020. Past-month use increased from 11.2% in 2019 to 19.7% in 2025. The state's 12.8 million residents supported $1.87 billion in sales in 2025. Illinois requires social equity provisions, with 185 of 575 licenses awarded to social equity applicants as of May 2026. The Illinois Department of Financial and Professional Regulation reported that out-of-state residents account for 18% of adult-use sales, driven by tourism and proximity to prohibition states. Possession limit: 1 ounce flower (residents), 0.5 ounces (non-residents). Home cultivation: medical patients only, 5 plants.

Massachusetts

Massachusetts legalized through Question 4 in November 2016, with sales beginning November 2018. Past-month use reached 22.4% in 2025, up from 14.1% in 2016. The Cannabis Control Commission reported $1.64 billion in sales in 2025. Massachusetts has the highest per-capita consumption among East Coast states, with daily use at 10.1%. The state's 403 licensed retailers serve 6.9 million residents. Possession limit: 1 ounce in public, 10 ounces at home. Home cultivation: 6 plants per person, 12 per residence.

Michigan

Michigan legalized through Proposal 1 in November 2018, with sales beginning December 2019. The state's 10 million residents supported $3.02 billion in sales in 2025, the third-largest state market after California and Illinois. Past-month use increased from 13.6% in 2018 to 21.8% in 2025. Michigan's Cannabis Regulatory Agency reported 1,638 active retail licenses as of May 2026, the highest per-capita retail density nationally. Average retail prices have declined 42% since 2020, from $14.50 per gram to $8.40, driven by oversupply. Possession limit: 2.5 ounces flower, 15 grams concentrate. Home cultivation: 12 plants per residence.

New York

New York legalized through the Marihuana Regulation and Taxation Act in March 2021, with retail sales beginning December 2022. The state's 19.5 million residents represent the largest untapped market on the East Coast. Past-month use reached 18.9% in 2025, up from 14.2% in 2021. The Office of Cannabis Management reported $1.23 billion in legal sales in 2025, though the illicit market remains dominant at an estimated $4-6 billion. New York has prioritized social equity licensing, with 463 of 712 retail licenses awarded to justice-involved individuals as of May 2026. Possession limit: 3 ounces flower, 24 grams concentrate. Home cultivation: medical patients only, 6 plants.

Ohio

Ohio legalized through Issue 2 in November 2023, with retail sales beginning August 2024. Past-month use increased from 10.8% in 2023 to 16.2% in early 2026. The Division of Cannabis Control reported $847 million in sales from August 2024 through April 2026. Ohio's rapid market growth—reaching $100 million monthly within six months—suggests pent-up demand in Midwest prohibition states. The state's 11.8 million residents support 137 active dispensaries as of May 2026. Possession limit: 2.5 ounces flower. Home cultivation: 6 plants per person, 12 per residence.

Texas

Texas maintains prohibition with a limited medical program (Compassionate Use Program) restricted to patients with epilepsy, terminal cancer, PTSD, and autism, with THC capped at 1%. Despite prohibition, past-month use reached 11.4% in 2025, up from 6.9% in 2015, driven by proximity to legal states and illicit market access. The state's 30 million residents represent the largest prohibition market. Legislative efforts to expand medical access or enact adult-use legalization have failed repeatedly, most recently in the 2023 session when House Bill 218 died in committee.

Washington

Washington legalized through Initiative 502 in November 2012, with sales beginning July 2014. Past-month use increased from 11.8% in 2012 to 22.1% in 2025. The Washington State Liquor and Cannabis Board reported $1.48 billion in sales in 2025. Washington merged its medical and adult-use programs in 2016, creating a unified regulatory framework. The state's 7.7 million residents support 538 licensed retailers. Washington has the highest excise tax rate nationally at 37%, contributing to persistent illicit market competition. Possession limit: 1 ounce flower, 7 grams concentrate. Home cultivation: medical patients only, 4-16 plants depending on authorization.

Market and Business Implications

Rising daily consumption has transformed cannabis from a vice market to a consumer packaged goods market, with implications for product development, pricing, distribution, and capital allocation.

Revenue Concentration Among Daily Users

Industry data consistently shows that daily or near-daily users account for 75-80% of total cannabis purchases despite representing 35-40% of consumers. This concentration exceeds that of alcohol, where daily drinkers account for approximately 50% of consumption. For operators, this dynamic drives loyalty program investment, subscription models, and bulk pricing strategies.

Curaleaf's 2025 data showed that customers who visit more than twice monthly spend an average of $3,200 annually, compared to $580 for customers who visit less than monthly. Green Thumb Industries reported that loyalty program members have a 68% higher lifetime value than non-members, with retention rates of 82% after 12 months compared to 41% for non-members.

Product Format Evolution

Flower remains the dominant product category at 45-50% of sales nationally, but its share has declined from 65-70% in 2015-2017 as alternative formats have gained adoption. Pre-rolls have emerged as the fastest-growing category, increasing from 8% of sales in 2020 to 18% in 2025, driven by convenience and social consumption occasions.

Vaporizers (cartridges and disposables) account for 25-30% of sales, with particularly high penetration among daily users who value discretion and convenience. Edibles represent 8-12% of sales, with beverages growing rapidly from a small base—increasing 340% between 2022 and 2025 according to BDSA data. Concentrates (dabs, wax, shatter) account for 6-8% of sales, concentrated among experienced consumers.

Average THC potency has increased across categories. Flower THC content averaged 24.3% in 2025, up from 13.2% in 2010. Vaporizer cartridges average 78-85% THC. Edibles are typically dosed at 5-10mg THC per serving, with 100mg per package in most states. High-potency products appeal to daily users seeking cost efficiency, as they deliver more THC per dollar spent.

Pricing Dynamics and Deflation

Wholesale and retail cannabis prices have declined substantially in mature markets due to oversupply, cultivation efficiency gains, and competition. In Oregon, wholesale flower prices fell from $1,800 per pound in 2016 to $380 per pound in 2025—a 79% decline. Michigan wholesale prices dropped from $3,200 per pound in 2020 to $1,100 in 2025. California wholesale prices averaged $950 per pound in 2025, down from $1,600 in 2018.

Retail price deflation has been less severe due to fixed costs and tax burdens, but still significant. The average price per gram of flower declined from $12.50 nationally in 2020 to $8.90 in 2025—a 29% decrease. Pre-roll prices fell from $8.50 to $6.20 per unit over the same period. Vaporizer cartridges declined from $42 to $34 per 0.5-gram unit.

Price deflation benefits consumers and may drive increased consumption through income effects, but pressures operator margins. Gross margins for multi-state operators declined from 50-55% in 2020 to 42-46% in 2025. Operators have responded by emphasizing branded products with higher margins, vertical integration to capture wholesale margins, and operational efficiency.

Impact on Adjacent Industries

The alcohol industry has monitored cannabis consumption trends closely, with several major beverage companies investing in cannabis ventures. Constellation Brands invested $4 billion in Canopy Growth between 2017 and 2018. Molson Coors formed a joint venture with HEXO to develop cannabis beverages. Anheuser-Busch InBev has explored CBD beverages through partnerships.

Survey data suggests substitution effects. A 2025 study published in the International Journal of Drug Policy found that 27% of cannabis consumers reported decreasing alcohol consumption after initiating regular cannabis use, with the effect strongest among daily cannabis users. Nielsen data shows that beer sales in legal cannabis states have grown 1.2 percentage points slower than in prohibition states since 2015, suggesting modest substitution.

The pharmaceutical industry faces potential disruption in several therapeutic categories. A 2024 study in Health Affairs found that Medicare Part D spending on prescription drugs for pain, anxiety, sleep, and nausea was 7-11% lower in medical cannabis states than in prohibition states, controlling for demographic factors. Opioid prescriptions have declined more rapidly in medical cannabis states, according to research published in JAMA Internal Medicine.

What Experts Say

Public health researchers, economists, and industry analysts offer divergent perspectives on whether rising consumption represents normalization of a relatively safe substance or a concerning public health trend.

Dr. Jonathan Caulkins, professor at Carnegie Mellon University and lead author of the May 2026 study showing daily cannabis use surpassing daily alcohol use, characterized the trend as a fundamental shift in American substance use patterns. According to Caulkins, the data reflects "a 50-year arc from prohibition to acceptance," with implications for public health policy that remain uncertain. His research team noted that while cannabis is generally less harmful than alcohol in terms of overdose risk and organ damage, daily use carries risks including cannabis use disorder, cognitive effects, and respiratory issues from smoking.

Dr. Nora Volkow, director of the National Institute on Drug Abuse, has expressed concern about rising daily use rates, particularly regarding high-potency products. In testimony before Congress in March 2026, Volkow stated that approximately 30% of daily cannabis users meet diagnostic criteria for cannabis use disorder under DSM-5 criteria, and that emergency department visits for cannabis-related issues have increased 60% since 2015 in states with legal markets. NIDA research indicates that daily use is associated with increased risk of psychotic disorders, particularly among individuals with genetic vulnerability.

Dr. Stanton Glantz, professor of medicine at University of California San Francisco, has drawn parallels between cannabis industry marketing tactics and historical tobacco industry practices. According to Glantz, the concentration of sales among daily users creates incentives for companies to promote heavy consumption through loyalty programs and high-potency products, similar to the alcohol industry's dependence on heavy drinkers. His research group has documented cannabis industry lobbying against potency caps and serving size limits.

Conversely, Dr. Ziva Cooper, director of the UCLA Center for Cannabis and Cannabinoids, has argued that rising consumption reflects therapeutic use by patients seeking alternatives to prescription medications. Cooper's research on cannabis as an opioid substitute suggests that increased cannabis use may be contributing to declining opioid overdose deaths, which fell 12% nationally between 2023 and 2025 after peaking in 2022. According to Cooper, the public health calculus should weigh cannabis risks against the risks of substances it replaces.

Economists have focused on market implications. Beau Whitney, senior economist at Whitney Economics, projects that the U.S. legal cannabis market will reach $52 billion by 2030, driven by continued state-level legalization and consumption growth. According to Whitney, daily users will account for 82% of sales by 2030, up from 78% currently, as occasional users remain price-sensitive while heavy users demonstrate brand loyalty and willingness to pay premium prices.

Industry executives emphasize that consumption growth reflects consumer choice in legal markets. Boris Jordan, executive chairman of Curaleaf, stated in the company's Q1 2026 earnings call that rising daily use demonstrates that "cannabis has become a routine part of wellness and relaxation for millions of Americans, similar to having a glass of wine with dinner." Jordan noted that Curaleaf's average customer is 42 years old with household income above $75,000